Dextran microspheres could enhance immune responses against PLGA nanospheres encapsulated with tetanus toxoid and Quillaja saponins after nasal immunization in rabbit

Pharmaceutical Development and Technology

Volumn 16, Issue 1, 2011, Pages 36-43

  Mohaghegh, Maliheh ^a   Tafaghodi, Mohsen ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Pharmaceutical Research Center   (Belgium)

Author keywords

Cross linked dextran microspheres; Nasal immunization; PLGA nanosphere; Quillaja saponin; Tetanus toxoid

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MICROSPHERE; NANOSPHERE; POLYGLACTIN; SAPONIN DERIVATIVE; SEPHADEX; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG STRUCTURE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; NANOENCAPSULATION; NASAL LAVAGE; NONHUMAN; PRIORITY JOURNAL; QUILLAJA; RABBIT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CROSS-LINKING REAGENTS; DEXTRANS; DRUG CARRIERS; DRUG STABILITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; NANOSPHERES; NASAL MUCOSA; PARTICLE SIZE; PLANT BARK; PLANT EXTRACTS; POLYGLYCOLIC ACID; QUILLAJA; RABBITS; SOLUBILITY; SURFACE PROPERTIES; TETANUS TOXOID;

EID: 78650794534     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903479962     Document Type: Article

References (50)

1. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009;61:140-157.
2. Jepson MA, Clark MA, Hirst BH. M cell targeting by lectins: A strategy for mucosal vaccination and drug delivery. Adv Drug Deliv Rev 2004;56:511-525.
3. Bowersock TL, Hogenesch H, Suckow M, Porter RE, Jackson R, Park H, Park K. Oral vaccination with alginate microsphere systems. J Controlled Release 1996;39:209-220.
4. Cho N-H, Seong S-Y, Chun K-H, Kim Y-H, Chan Kwon I, Ahn B-Y, Jeong S. Novel mucosal immunization with polysaccharideprotein conjugates entrapped in alginate microspheres. J Controlled Release 1998;53:215-224.
5. Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H. Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol 2001;83:93-105.
6. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005;57:411-430.
7. Diwan M, Khar RK, Talwar GP. Tetanus toxoid loaded 'preformed microspheres' of cross-linked dextran. Vaccine 2001;19:3853-3859.
8. Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: An analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 2000;50:129-146.
9. Newman KD, Sosnowski DL, Kwon GS, Samuel J. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci 1998;87:1421-1427.
10. Venkataprasad N, Coombes AGA, Singh M, Rohde M, Wilkinson K, Hudecz F, Davis SS, Vordermeier HM. Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine 1999;17: 1814-1819.
11. Sajadi Tabassi SA, Tafaghodi M, Jaafari MR. Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm 2008;360:12-17.
12. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640-1665.
13. Illum L, Jorgensen H, Bisgaard H, Krogsgaard O, Rossing N. Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm 1987;39:189-199.
14. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995;13:1263-1276.
15. Cox JC, Coulter AR. Adjuvants - a classification and review of their modes of action. Vaccine 1997;15:248-256.
16. Lacaille-Dubois MA, Saponins as immunoadjuvants and immunostimulants. In: Wagner H, editor. Immunomodulatory agents from plants. Switzerland: Birkhauser Verlag; 1999. pp 243-272.
17. Sun H-X, Xie Y, Ye Y-P. Advances in saponin-based adjuvants. Vaccine 2009;27:1787-1796.
18. Ellis JA, West KH, Waldner C, Rhodes C. Efficacy of a saponinadjuvanted inactivated respiratory syncytial virus vaccine in calves. Can Vet J 2005;46:155-162.
19. Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 2006;40:53-59.
20. Diwan M, Park TG. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J Controlled Release 2001;73:233-244.
21. Waterborg JH, Quantitation of proteins. In: Walker J, editor. The protein protocols handbook. New Jersey: Humana Press; 2002. pp 3-36.
22. Cornaz A-L, De Ascentis A, Colombo P, Buri P. In vitro characteristics of nicotine microspheres for transnasal delivery. Int J Pharm 1996;129:175-183.
23. Tafaghodi M, Sajadi Tabasi SA, Jaafari MR. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm 2006;319:37-43.
24. Eyles JE, Williamson ED, Alpar HO. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: Studies on the effect of vehicle volume. Int J Pharm 1999;189:75-79.
25. Alpar HO, Almeida AJ. Identification of some of the physicochemical characteristics of microspheres which influence the induction the immune response following mucosal delivery. Eur J Pharm Biopharm 1994;40:198-202.
26. Stuart BO. Deposition and clearance of inhaled particles. Environ Health Perspect 1984;55:369-390.
27. Payne JM, Sansom BF, Garner RJ, Thomson AR, Miles BJ. Uptake of small resin particles (1-5 micron diameter) by the alimetary canal of the calf. Nature 1960;188:586-587.
28. Chen KS, Quinnan GV Jr. Secretory immunoglobulin A antibody response is conserved in aged mice following oral immunization with influenza virus vaccine. J Gen Virol 1989;70 (Pt 12):3291-3296.
29. Tafaghodi M, Jaafari MR, Sajadi Tabassi sA, Diwan M, Samuel J. Utilization of particulate and immuno-modulating adjuvants for enhancement of immune response against tumors antigenic markers. Iranian J Basic Med Sci 2004;6:14-23.
30. Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Controlled Release 2002;85:247-262.
31. Jain AK, Khar RK, Ahmed FJ, Diwan PV. Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm 2008;69:426-435.
32. Ryden L, Edman P. Effect of polymers and microspheres on the nasal absorption of insulin in rats. Int J Pharm. 1982;83:1-10.
33. Pereswetoff-Morath L, Edman P. Dextran microspheres as a potential nasal drug delivery system for insulin - in vitro and in vivo properties. Int J Pharm 1995;124:37-44.
34. Chandler SG, Ilium L, Thomas NW. Nasal absorption in rats. II. Effect of enhancers on insulin absorption and nasal histology. Int J Pharm 1991;76:61-70.
35. Illum L, Farraj NF, Davis SS, Johansen BR, O'Hagan DT. Investigation of the nasal absorption of biosynthetic human growth hormone in sheep - use of a bioadhesive microsphere delivery system. Int J Pharm 1990;63:207-211.
36. Oechslein CR, Fricker G, Kissel T. Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems. Int J Pharm 1996;139:25-32.
37. Gill IJ, Fisher AN, Farraj N, Pitt CG, Davis SS, Illum L. Intranasal absorption of granulocyte-colony stimulating factor (G-CSF) from powder formulations, in sheep. Eur J Pharm Sci 1998;6:1-10.
38. Pereswetoff-Morath L, Edman P. Immunological consequences of nasal drug delivery in dextran microspheres and ethyl(hydroxyethyl)cellulose in rats. Int J Pharm 1996;128:23-28.
39. O'Hagan DT. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat 1996;189:477-482.
40. O'Hagan DT, Rafferty D, Wharton S, Illum L. Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine 1993;11:660-664.
41. Rydell N, Sjoholm I. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 2004;22:1265-1274.
42. Rydell N, Sjoholm I. Mucosal vaccination against diphtheria using starch microparticles as adjuvant for crossreacting material (CRM197) of diphtheria toxin. Vaccine 2005;23:2775-2783.
43. Stertman L, Lundgren E, Sjoholm I. Starch microparticles as a vaccine adjuvant: Only uptake in Peyer's patches decides the profile of the immune response. Vaccine 2006;24:3661-3668.
44. Stertman L, Strindelius L, Sjoholm I. Starch microparticles as an adjuvant in immunisation: Effect of route of administration on the immune response in mice. Vaccine 2004;22:2863-2872.
45. Illum L, Fisher AN, Jabbal-Gill I, Davis SS. Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm 2001;222:109-119.
46. Bjork E, Edman P. Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int J Pharm 1990;62:187-192.
47. Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev 1998;29:185-194.
48. Kidane A, Guimond P, Rob Ju T-C, Sanchez M, Gibson J, North A, HogenEsch H, Bowersock TL. Effects of cellulose derivatives and poly(ethylene oxide)-poly(propylene oxide) tri-block copolymers (Pluronic(R)surfactants) on the properties of alginate based microspheres and their interactions with phagocytic cells. J Controlled Release 2002;85:181-189.
49. Tafaghodi M, Sajadi Tabassi SA, Jaafari M-R, Zakavi SR, Momen Nejad M. Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. Int J Pharm 2004;280:125-135.
50. Tafaghodi M, Sajadi Tabasi SA, Jaafari MR. Nasal immunization study by PLGA nanospheres encapsulated with tetanus toxoid and CpG-ODN. Iranian J Pharm Res 2007;6:151-158.